Pharmacogenomic discovery using cell-based models

Pharmacological Reviews

Volumn 61, Issue 4, 2009, Pages 413-429

  Welsh, Marleen ^a   Mangravite, Lara ^b   Medina, Marisa Wong ^b   Tantisira, Kelan ^c   Zhang, Wei ^a   Huang, R Stephanie ^a   McLeod, Howard ^d   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BISANTRENE; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GELDANAMYCIN; GEMCITABINE; INOSINE DERIVATIVE; PACLITAXEL; PREDNISOLONE; TRIAZINATE;

AFRICA; CELL LINE; CHINESE; DRUG RESPONSE; EUROPE; EX VIVO STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VIVO STUDY; JAPANESE; LYMPHOBLASTOID CELL LINE; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOTRANSFORMATION; CELLS, CULTURED; HUMANS; PHARMACOGENETICS;

EID: 73449118589     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.109.001461     Document Type: Review

References (163)

1. 1000 Genomes Project (2007) Meeting report: a workshop to plan a deep catalog of human genetic variation; 2007 Sep 17-18; Cambridge, UK. Available at http://www.1000genomes.org/files/1000Genomes-MeetingReport.pdf.
2. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, et al. (2008) The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 325:859-868.
3. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. (2006) Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318:521-529.
4. Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. (2005) Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J 5:157-165.
5. Bauer JW, Bilgic H, and Baechler EC (2009) Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nat Rev Rheumatol 5:257-265.
6. Bleibel WK, Duan S, Huang RS, Kistner EO, Shukla SJ, Wu X, Badner JA, and Dolan ME (2009) Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet 125:173-180.
7. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et al. (2008) MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7:1-9.
8. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, et al. (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6:1483-1491.
9. Blower PE, Yang C, Fligner MA, Verducci JS, Yu L, Richman S, and Weinstein JN (2002) Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J 2:259-271.
10. Burkhardt R, Kenny EE, Lowe JK, Birkeland A, Josowitz R, Noel M, Salit J, Maller JB, Pe'er I, Daly MJ, et al. (2008) Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol 28:2078-2084.
11. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Jain A, Kouros-Mehr H, Fridlyand J, et al. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5:853-867.
12. Cann HM (1992) CEPH maps. Curr Opin Genet Dev 2:393-399.
13. Chagnon YC, Roy MA, Bureau A, Mérette C, and MaziadeM(2008) Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes. Schizophr Res 100:281-290.
14. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, and Ridker PM (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821-2827.
15. Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, Johns SJ, Ferrin TE, Kwok P, and Giacomini KM (2009) Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 9:127-136.
16. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, and Spielman RS (2003) Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 33:422-425.
17. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, and Burdick JT (2005) Mapping determinants of human gene expression by regional and genome-wide association. Nature 437:1365-1369.
18. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, De Jager PL, Shaw SY, Wolfish CS, Slavik JM, Cotsapas C, et al. (2008) Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 4:e1000287.
19. Clayman CB, Arnold J, Hockwald RS, Yount EH Jr, Edgcomb JH, and Alving AS (1952) Toxicity of primaquine in Caucasians. JAMA 149:1563-1568.
20. Cloos J, de Boer WP, Snel MH, van den Ijssel P, Ylstra B, Leemans CR, Brakenhoff RH, and Braakhuis BJ (2006) Microarray analysis of bleomycin-exposed lymphoblastoid cells for identifying cancer susceptibility genes. Mol Cancer Res 4:71-77.
21. Cloos J, Nieuwenhuis EJ, Boomsma DI, Kuik DJ, van der Sterre ML, Arwert F, Snow GB, and Braakhuis BJ (1999) Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst 91:1125-1130.
22. Dai Z, Barbacioru C, Huang Y, and Sadée W (2006) Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. Pharm Res 23:336-349.
23. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, and White R (1990) Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics 6:575-577.
24. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, and Zanger UM (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547-558.
25. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, and Badner JA (2004) Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 64:4353-4356.
26. Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, and Dolan ME (2007) Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 67:5425-5433.
27. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, et al. (2008) Genetic architecture of transcript-level variation in humans. Am J Hum Genet 82:1101-1113.
28. Elbein SC, Chu WS, Das SK, Yao-Borengasser A, Hasstedt SJ, Wang H, Rasouli N, and Kern PA (2007) Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia 50:1621-1630.
29. Engen RM, Marsh S, Van Booven DJ, and McLeod HL (2006) Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 7:1641-1648.
30. Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, et al. (2006) The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol 290:F905-F912.
31. Estey E, Plunkett W, Dixon D, Keating M, McCredie K, and Freireich EJ (1987) Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1:580-583.
32. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, et al. (2001) Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19:2293-301.
33. Evans WE, Horner M, Chu YQ, Kalwinsky D, and Roberts WM (1991) Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985-989.
34. Feng WH, Hong G, Delecluse HJ, and Kenney SC (2004) Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 78:1893-902.
35. Fry RC, Svensson JP, Valiathan C, Wang E, Hogan BJ, Bhattacharya S, Bugni JM, Whittaker CA, and Samson LD (2008) Genomic predictors of interindividual differences in response to DNA damaging agents. Genes Dev 22:2621-2626.
36. Fujita T, Brown C, Carlson EJ, Taylor T, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Fujita K, Castro R, et al. (2005) Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 15:201-209.
37. Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, and Dumontet C (2003) Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 122:53-60.
38. Gamazon ER, Zhang W, Huang RS, Dolan ME, and Cox NJ (2009) A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics 19:829-832.
39. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, et al. (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 4:e4576.
40. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122.
41. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, and Israel MA (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67:2456-2468.
42. Gipps EM and Kidson C (1984) Cellular radiosensitivity: expression of an MS susceptibility gene? Neurology 34:808-811.
43. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, et al. (2004) Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 65:512-519.
44. Hartford C, Yang W, Cheng C, Fan Y, Liu W, Treviño L, Pounds S, Neale G, Raimondi SC, Bogni A, et al. (2007) Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia 21:2128-2136.
45. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, and Dolan ME (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113:2145-2153.
46. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, et al. (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542.
47. Huang N, Agrawal V, Giacomini KM, and Miller WL (2008a) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 105:1733-1738.
48. Huang R, Wallqvist A, Thanki N, and Covell DG (2005a) Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics J 5:381-399.
49. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, et al. (2007a) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A 104:9758-9763.
50. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL, Das S, and Dolan ME (2008b) Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 68:3161-3168.
51. Huang RS, Duan S, Kistner EO, Hartford CM, and Dolan ME (2008c) Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7:3038-3046.
52. Huang RS, Duan S, Kistner EO, Zhang W, Bleibel WK, Cox NJ, and Dolan ME (2008d) Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics 18:545-549.
53. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, Schweitzer AC, Blume JE, and Dolan ME (2007b) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 81:427-437.
54. Huang SM and Temple R (2008) Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 84:287-294.
55. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, and Sadẽe W (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294-301.
56. Huang Y, Dai Z, Barbacioru C, and Sadée W (2005b) Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65:7446-7454.
57. Imray FP, Smith PJ, Relf W, and Kidson C (1984) Wilms' tumour: association with cellular sensitivity to mitomycin C in patients and first-degree relatives. Lancet 1:1148-1151.
58. Innocenti F, Mirkov S, Nagasubramanian R, Ramírez J, Liu W, Bleibel WK, Shukla SJ, Hennessy K, Rosner GL, Cook E Jr, et al. (2009) The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol 63:881-887.
59. International HapMap Consortium (2003) The International HapMap Project. Nature 426:789-796.
60. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299-320.
61. International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851-861.
62. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764.
63. Jarjanazi H, Kiefer J, Savas S, Briollais L, Tuzmen S, Pabalan N, Ibrahim-Zada I, Mousses S, and Ozcelik H (2008) Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. Hum Mutat 29:461-467.
64. Jeon JP, Shim SM, Nam HY, Baik SY, Kim JW, and Han BG (2007) Copy number increase of 1p36.33 and mitochondrial genome amplification in Epstein-Barr virus-transformed lymphoblastoid cell lines. Cancer Genet Cytogenet 173:122-130.
65. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, et al. (2006a) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9:485-495.
66. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, McNamara, Xia H, et al. (2006b) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 103:7817-7822.
67. Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, Saffen D, Dai Z, Wang D, and Sadée W (2008) Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 18:781-791.
68. Jones TS, Yang W, Evans WE, and Relling MV (2007) Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 81:729-734.
69. Kim C, Taniyama Y, and Paik S (2009) Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. Arch Pathol Lab Med 133:855-859.
70. Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, Ujjin P, Shimada T, Guengerich FP, Parkinson A, et al. (2003) Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 13:689-695.
71. Klees TM, Sheffels P, Thummel KE, and Kharasch ED (2005) Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology 102:550-556.
72. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, Rieder MJ, Simon JA, Hulley SB, Waters D, et al. (2008) Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117:1537-1544.
73. Kudaravalli S, Veyrieras JB, Stranger BE, Dermitzakis ET, and Pritchard JK (2009) Gene expression levels are a target of recent natural selection in the human genome. Mol Biol Evol 26:649-658.
74. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
75. Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, and Ribeiro R (2007) Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 323:935-945.
76. Le Morvan V, Bellott R, Moisan F, Mathoulin-Pélissier S, Bonnet J, and Robert J (2006) Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-á-vis the NCI-60 panel. Pharmacogenomics 7:843-852.
77. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, and Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78:330-341.
78. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, and Theodorescu D (2007) A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 104:13086-91.
79. Lennard L, Lilleyman JS, Van Loon J, and Weinshilboum RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-229.
80. Lennard L, Van Loon JA, Lilleyman JS, and Weinshilboum RM.(1987) Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41:18-25.
81. Lennard L, Van Loon JA, and Weinshilboum RM (1989) Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46:149-154.
82. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, and Wang L (2008) Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 68:7050-7058.
83. Ling PD and Huls HM (2005) Isolation and immortalization of lymphocytes. Curr Protoc Mol Biol Chapter 28:Unit 28 2.
84. Liu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, Wang WB, and Chen JY (2004) Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 23:2531-2539.
85. Liu R, Blower PE, Pham AN, Fang J, Dai Z, Wise C, Green B, Teitel CH, Ning B, Ling W, et al. (2007a) Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol 72:1637-1646.
86. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH Jr, et al. (2007b) Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13:6788-6795.
87. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 350:2129- 2139.
88. Ma Y, Ding Z, Qian Y, Shi X, Castranova V, Harner EJ, and Guo L (2006) Predicting cancer drug response by proteomic profiling. Clin Cancer Res 12:4583-4589.
89. Ma Y, Ding Z, Qian Y, Wan YW, Tosun K, Shi X, Castranova V, Harner EJ, and Guo NL (2009) An integrative genomic and proteomic approach to chemosensitivity prediction. Int J Oncol 34:107-115.
90. Maitland ML, Vasisht K, and Ratain MJ (2006) TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 27:432-437.
91. Mardis ER (2008) The impact of next-generation sequencing technology on genetics. Trends Genet 24:133-141.
92. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, and Evans WE (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97:73-80.
93. McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, and Fuchs CS (2002) Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 94:1160-1167.
94. McLeod HL, Krynetski EY, Relling MV, and Evans WE (2000) Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14:567-572.
95. Medina MW, Gao F, Ruan W, Rotter JI, and Krauss RM (2008) Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118:355-362.
96. Miller WL, Huang N, Agrawal V, and Giacomini KM (2009) Genetic variation in human P450 oxidoreductase. Mol Cell Endocrinol 300:180-184.
97. Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, Wong J, McNeil E, and Bishop JF (2003) Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 14:449-454.
98. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, and Cheung VG (2004) Genetic analysis of genome-wide variation in human gene expression. Nature 430:743-747.
99. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Espina V, et al. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100:14229-34.
100. O'Donnell PH and Dolan ME (2009) Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 15:4806-4814.
101. Okabe M, Szakács G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, and Gottesman MM (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081-3091.
102. Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J, Ferrin TE, Herskowitz I, and Giacomini KM (2003) Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13:297-301.
103. Owen RP, Gray JH, Taylor TR, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, and Giacomini KM (2005) Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet Genomics 15:83-90.
104. Owen RP, Lagpacan LL, Taylor TR, De La Cruz M, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, and Giacomini KM (2006) Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab Dispos 34:12-15.
105. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500.
106. Pham AN, Wang J, Fang J, Gao X, Zhang Y, Blower PE, Sadée W, and Huang Y (2009) Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins. Pharm Res 26:936-945.
107. Poonkuzhali B, Lamba J, Strom S, Sparreboom A, Thummel K, Watkins P, and Schuetz E (2008) Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos 36:780-795.
108. Poot M, Gollahon KA, and Rabinovitch PS (1999) Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet 104:10-14.
109. Pottier N, Cheok MH, Yang W, Assem M, Tracey L, Obenauer JC, Panetta JC, Relling MV, and Evans WE (2007) Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet 16:2261-2271.
110. Price AL, Patterson N, Hancks DC, Myers S, Reich D, Cheung VG, and Spielman RS (2008) Effects of cis and trans genetic ancestry on gene expression in African Americans. PLoS Genet 4:e1000294.
111. Puyo S, Le Morvan V, and Robert J (2008) Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro. Mol Diagn Ther 12:225-234.
112. Ramírez J, Komoroski BJ, Mirkov S, Graber AY, Fackenthal DL, Schuetz EG, Das S, Ratain MJ, Innocenti F, and Strom SC (2006) Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics 16:79-86.
113. Ratain MJ (2006) From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res 12:1658-1660.
114. Raza A, Gezer S, Anderson J, Lykins J, Bennett J, Browman G, Goldberg J, Larson R, Vogler R, and Preisler HD (1992) Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp Hematol 20:1194-200.
115. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, and Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008.
116. Rogers SJ, Box C, Chambers P, Barbachano Y, Nutting CM, Rhŷs-Evans P, Workman P, Harrington KJ, and Eccles SA (2009) Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol 218:122-130.
117. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235.
118. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, et al. (2008) An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 3:e1908.
119. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, and Lu X (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8:781-794.
120. Sasaki S, Kobunai T, Kitayama J, and Nagawa H (2008) DNA methylation and sensitivity to antimetabolites in cancer cell lines. Oncol Rep 19:407-412.
121. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244.
122. Schmiegelow K, Forestier E, Kristinsson J, Söderhäll S, Vettenranta K, Weinshilboum R, Wesenberg F, and Nordic Society of Paediatric Haematology and Oncology (2009) Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 23:557-564.
123. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, et al. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6:820-832.
124. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, and Issa JP (2007) Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 67:11335-43.
125. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823.
126. Shukla SJ and Dolan ME (2005) Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics 6:303-310.
127. Shukla SJ, Duan S, Badner JA, Wu X, and Dolan ME (2008) Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 18:253-262.
128. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, and Dolan ME (2009) Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics 3:128-142.
129. Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, Rotter JI, Nickerson DA, Yang H, Saad M, et al. (2006) Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol 97:843-850.
130. Smirnov DA, Morley M, Shin E, Spielman RS, and Cheung VG (2009) Genetic analysis of radiation-induced changes in human gene expression. Nature 459:587-591.
131. Sorani MD, Zador Z, Hurowitz E, Yan D, Giacomini KM, and Manley GT (2008) Novel variants in human Aquaporin-4 reduce cellular water permeability. Hum Mol Genet 17:2379-2389.
132. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, and Cheung VG (2007) Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet 39:226-231.
133. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, et al. (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 98:10787-92.
134. Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC, and Pommier Y (2008) Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 7:10-18.
135. Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, and Akey JM (2007) Gene-expression variation within and among human populations. Am J Hum Genet 80:502-509.
136. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavaré S, et al. (2005) Genome-wide associations of gene expression variation in humans. PLoS Genet 1:e78.
137. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, et al. (2007a) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315:848-853.
138. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, et al. (2007b) Population genomics of human gene expression. Nat Genet 39:1217-1224.
139. Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129-137.
140. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E, and Weinshilboum R (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15:17-30.
141. Tahara H, Yee SW, Urban TJ, Hesselson S, Castro RA, Kawamoto M, Stryke D, Johns SJ, Ferrin TE, Kwok PY, et al. (2009) Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J Pharmacol Exp Ther 329:262-271.
142. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, and Evans WE (1996) Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58:694-702.
143. Tozzi V (2009) Pharmacogenetics of antiretrovirals. Antiviral Res doi: 10.1016/j.antiviral.2009.09.001.
144. Urban TJ, Gallagher RC, Brown C, Castro RA, Lagpacan LL, Brett CM, Taylor TR, Carlson EJ, Ferrin TE, Burchard EG, et al. (2006a) Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol 70:1602-1611.
145. Urban TJ, Sebro R, Hurowitz EH, Leabman MK, Badagnani I, Lagpacan LL, Risch N, and Giacomini KM (2006b) Functional genomics of membrane transporters in human populations. Genome Res 16:223-230.
146. Urban TJ, Yang C, Lagpacan LL, Brown C, Castro RA, Taylor TR, Huang CC, Stryke D, Johns SJ, Kawamoto M, et al. (2007) Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics 17:773-782.
147. Waddell N, Ten Haaf A, Marsh A, Johnson J, Walker LC, Investigators K, Gongora M, Brown M, Grover P, Girolami M, et al. (2008) BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression. PLoS Genet 4:e1000080.
148. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, and Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9:489-499.
149. Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, et al. (2008) Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res 14:3503-3513.
150. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, and Weinshilboum RM (2005) Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A 102:9394-9399.
151. Watanabe A, Taniguchi M, and Sasaki S (2003) Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs 14:801-807.
152. Watters JW, Kraja A, Meucci MA, Province MA, and McLeod HL (2004) Genomewide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 101:11809-14.
153. Weinshilboum RM and Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662.
154. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349.
155. Yang J, Bogni A, Cheng C, Bleibel WK, Cai X, Fan Y, Yang W, Rocha JC, Pei D, Liu W, et al. (2008) Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Clin Pharmacol Ther 84:691-697.
156. Yee SW, Shima JE, Hesselson S, Nguyen L, De Val S, Lafond RJ, Kawamoto M, Johns SJ, Stryke D, Kwok PY, et al. (2009) Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). J Pharmacol Exp Ther 328:699-707.
157. Yen-Revollo JL, Auman JT, and McLeod HL (2008) Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics 9:1639-1645.
158. Young D (2006) Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling. Am J Health Syst Pharm 63:2286-2296.
159. Zhang W, Duan S, Bleibel WK, Wisel SA, Huang RS, Wu X, He L, Clark TA, Chen TX, Schweitzer AC, et al. (2009) Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet 125:81-93.
160. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, et al. (2008a) Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 82:631-640.
161. Zhang W, Liu W, Poradosu E, and Ratain MJ (2008b) Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. Hum Genomics 3:53-70.
162. Zhang W, Ratain MJ, and Dolan ME (2008c) The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights 2:15-23.
163. Zhou SF, Liu JP, and Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295.